1
|
Yeung PSW, Miller P, Lai-Nyugen TB, Cheng P, Ibrahim A, Shi RZ, Bowen RA, Luo RY. Mass spectrometry quantitation of immunosuppressive drugs in clinical specimens using online solid-phase extraction and accurate-mass full scan-single ion monitoring. J Mass Spectrom Adv Clin Lab 2023; 28:99-104. [PMID: 36937810 PMCID: PMC10014293 DOI: 10.1016/j.jmsacl.2023.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 03/03/2023] [Accepted: 03/05/2023] [Indexed: 03/09/2023] Open
Abstract
Introduction Therapeutic drug monitoring (TDM) of immunosuppressants is essential for optimal care of transplant patients. Immunoassays and liquid chromatography-mass spectrometry (LC-MS) are the most commonly used methods for TDM. However, immunoassays can suffer from interference from heterophile antibodies and structurally similar drugs and metabolites. Additionally, nominal-mass LC-MS assays can be difficult to optimize and are limited in the number of detectable compounds. Objectives The aim of this study was to implement a mass spectrometry-based test for immunosuppressant TDM using online solid-phase extraction (SPE) and accurate-mass full scan-single ion monitoring (FS-SIM) data acquisition mode. Methods LC-MS analysis was performed on a TLX-2 multi-channel HPLC with a Q-Exactive Plus mass spectrometer. TurboFlow online SPE was used for sample clean up. The accurate-mass MS was set to positive electrospray ionization mode with FS-SIM for quantitation of tacrolimus, sirolimus, everolimus, and cyclosporine A. MS2 fragmentation pattern was used for compound confirmation. Results The method was validated in terms of precision, analytical bias, limit of quantitation, linearity, carryover, sample stability, and interference. Quantitation of tacrolimus, sirolimus, everolimus, and cyclosporine A correlated well with results from an independent reference laboratory (r = 0.926-0.984). Conclusions Accurate-mass FS-SIM can be successfully utilized for immunosuppressant TDM with good correlation with results generated by standard methods. TurboFlow online SPE allows for a simple "protein crash and shoot" sample preparation protocol. Compared to traditional MRM, analyte quantitation by FS-SIM facilitates a streamlined assay optimization process.
Collapse
Key Words
- Accurate-mass
- CAP, College of American Pathologists
- CLSI, Clinical & Laboratory Standards Institute
- CV, coefficient of variation
- ESI, electrospray ionization
- FS-SIM, full scan-single ion monitoring
- Full scan single-ion monitoring
- HCD, high-energy C-trap dissociation
- IRB, Institutional Review Board
- Immunosuppressive drugs
- LC-MS, liquid chromatography-mass spectrometry
- LDT, laboratory developed test
- MRM, multiple reaction monitoring
- Mass spectrometry
- Online solid-phase extraction
- SD, standard deviation
- SPE, solid-phase extraction
- TDM, therapeutic drug monitoring
- Therapeutic drug monitoring
Collapse
Affiliation(s)
- Priscilla S.-W. Yeung
- Department of Pathology, Stanford University, Stanford, CA, USA
- Clinical Laboratories, Stanford Health Care, Palo Alto, CA, USA
| | - Paige Miller
- Clinical Laboratories, Stanford Health Care, Palo Alto, CA, USA
| | | | - Phil Cheng
- Clinical Laboratories, Stanford Health Care, Palo Alto, CA, USA
| | - Amira Ibrahim
- Clinical Laboratories, Stanford Health Care, Palo Alto, CA, USA
| | - Run-Zhang Shi
- Department of Pathology, Stanford University, Stanford, CA, USA
- Clinical Laboratories, Stanford Health Care, Palo Alto, CA, USA
| | - Raffick A.R. Bowen
- Department of Pathology, Stanford University, Stanford, CA, USA
- Clinical Laboratories, Stanford Health Care, Palo Alto, CA, USA
| | - Ruben Yiqi Luo
- Department of Pathology, Stanford University, Stanford, CA, USA
- Clinical Laboratories, Stanford Health Care, Palo Alto, CA, USA
- Corresponding author at: 3375 Hillview Ave, Palo Alto, CA 94304, USA.
| |
Collapse
|
2
|
Sens A, Rischke S, Hahnefeld L, Dorochow E, Schäfer SMG, Thomas D, Köhm M, Geisslinger G, Behrens F, Gurke R. Pre-analytical sample handling standardization for reliable measurement of metabolites and lipids in LC-MS-based clinical research. J Mass Spectrom Adv Clin Lab 2023; 28:35-46. [PMID: 36872954 PMCID: PMC9975683 DOI: 10.1016/j.jmsacl.2023.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 02/09/2023] [Accepted: 02/13/2023] [Indexed: 02/18/2023] Open
Abstract
The emerging disciplines of lipidomics and metabolomics show great potential for the discovery of diagnostic biomarkers, but appropriate pre-analytical sample-handling procedures are critical because several analytes are prone to ex vivo distortions during sample collection. To test how the intermediate storage temperature and storage period of plasma samples from K3EDTA whole-blood collection tubes affect analyte concentrations, we assessed samples from non-fasting healthy volunteers (n = 9) for a broad spectrum of metabolites, including lipids and lipid mediators, using a well-established LC-MS-based platform. We used a fold change-based approach as a relative measure of analyte stability to evaluate 489 analytes, employing a combination of targeted LC-MS/MS and LC-HRMS screening. The concentrations of many analytes were found to be reliable, often justifying less strict sample handling; however, certain analytes were unstable, supporting the need for meticulous processing. We make four data-driven recommendations for sample-handling protocols with varying degrees of stringency, based on the maximum number of analytes and the feasibility of routine clinical implementation. These protocols also enable the simple evaluation of biomarker candidates based on their analyte-specific vulnerability to ex vivo distortions. In summary, pre-analytical sample handling has a major effect on the suitability of certain metabolites as biomarkers, including several lipids and lipid mediators. Our sample-handling recommendations will increase the reliability and quality of samples when such metabolites are necessary for routine clinical diagnosis.
Collapse
Key Words
- 1-AG, 1-arachidonoyl glycerol
- 1-LG, 1-linoleoyl glycerol
- 2-AG, 2-arachidonoyl glycerol
- 2-LG, 2- linoleoyl glycerol
- ACN, acetonitrile
- AEA, arachidonoyl ethanolamide
- BHT, 2,6-di-tert-butyl-4-methylphenol
- CAR, carnitine
- EC, endocannabinoid
- FC, fold change
- FT, freezing temperature/storage in ice water
- HETE, hydroxyeicosatetraenoate
- HRMS, high-resolution mass spectrometry
- IRB, Institutional Review Board
- IS, internal standard
- K3EDTA plasma sampling
- K3EDTA, tripotassium ethylenediaminetetraacetic acid
- LC, liquid chromatography
- LEA, linoleoyl ethanolamide
- LLE, liquid–liquid extraction
- LLOQ, lowest limit of quantification
- LPA, lysophosphatidic acid
- LPC O, lysophosphatidylcholine-ether
- LPC, lysophosphatidylcholine
- LPE, lysophosphatidylethanolamine
- LPG, lysophosphatidylglycerol
- LPI, lysophosphatic inositol
- Lipidomics
- MS/MS, tandem mass spectrometry
- MTBE, methyl tertiary-butyl ether
- MeOH, methanol
- Metabolomics
- OEA, oleoyl ethanolamide
- PBS, phosphate-buffered saline
- PC, phohsphatidylcholine
- PE, phosphotidylethanolamine
- PEA, palmitoyl ethanolamide
- PI, phosphatidylinositol
- Pre-analytics
- QC, quality control
- REC, Research Ethics Committee
- RT, room temperature
- Ref, reference sample
- SEA, stearoyl ethanolamide
- SPE, solid-phase extraction
- STD, calibration standard
- Sampling protocol
- VEA, vaccenic acid ethanolamid
- WB, whole blood
Collapse
Affiliation(s)
- A Sens
- Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - S Rischke
- Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - L Hahnefeld
- Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern-Kai 7, 60590 Frankfurt am Main, Germany.,Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany
| | - E Dorochow
- Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - S M G Schäfer
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany
| | - D Thomas
- Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern-Kai 7, 60590 Frankfurt am Main, Germany.,Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany
| | - M Köhm
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.,Rheumatology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - G Geisslinger
- Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern-Kai 7, 60590 Frankfurt am Main, Germany.,Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany
| | - F Behrens
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.,Rheumatology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - R Gurke
- Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern-Kai 7, 60590 Frankfurt am Main, Germany.,Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany
| |
Collapse
|
3
|
Kratz D, Thomas D, Gurke R. Endocannabinoids as potential biomarkers: It's all about pre-analytics. J Mass Spectrom Adv Clin Lab 2021; 22:56-63. [PMID: 34939056 DOI: 10.1016/j.jmsacl.2021.11.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Revised: 11/01/2021] [Accepted: 11/05/2021] [Indexed: 11/17/2022] Open
Abstract
Introduction Arachidonoyl ethanolamide (AEA) and 2-arachidonoyl glycerol (2-AG) are central lipid mediators of the endocannabinoid system. They are highly relevant due to their involvement in a wide variety of inflammatory, metabolic or malign diseases. Further elucidation of their modes of action and use as biomarkers in an easily accessible matrix, like blood, is restricted by their susceptibility to deviations during blood sampling and physiological co-dependences, which results in high variability of reported concentrations in low ng/mL ranges. Objectives The objective of this review is the identification of critical parameters during the pre-analytical phase and proposal of minimum requirements for reliable determination of endocannabinoids (ECs) in blood samples. Methods Reported physiological processes influencing the EC concentrations were put into context with published pre-analytical research and stability data from bioanalytical method validation. Results The cause for variability in EC concentrations is versatile. In part, they are caused by inter-individual factors like sex, metabolic status and/or diurnal changes. Nevertheless, enzymatic activity in freshly drawn blood samples is the main reason for changing concentrations of AEA and 2-AG, besides additional non-enzymatic isomerization of the latter. Conclusion Blood samples for EC analyses require immediate processing at low temperatures (>0 °C) to maintain sample integrity. Standardization of the respective blood tube or anti-coagulant, sampling time point, applied centrifugal force and complete processing time can further decrease variability caused by sample handling. Nevertheless, extensive characterization of study participants is needed to reduce distortion of clinical data caused by co-variables and facilitate research on the endocannabinoid system.
Collapse
Key Words
- (U)HPLC, (ultra) high performance liquid chromatography
- 1-AG, 1-arachidonoyl glycerol
- 2-AG, 2-arachidonoyl glycerol
- 2-Arachidonoyl glycerol
- AEA, arachidonoyl ethanolamide
- Anandamide
- BMI, body mass index
- Blood sampling
- CBR, cannabinoid receptor
- EC-like, endocannabinoid-like
- ECS, endocannabinoid system
- ECs, endocannabinoids
- EDTA, ethylenediaminetetraacetic acid
- Endocannabinoid
- FAAH, fatty acid amide hydrolase
- FT, freezing temperature
- FTC, freeze–thaw cycles
- HDL, high density lipo protein
- KSCN, potassium thiocyanate
- LLE, liquid–liquid extraction
- MAGL, monoacylglycerol lipase
- MS/MS, tandem mass spectrometry
- O-AEA, virodhamine
- OEA, oleoyl ethanolamide
- PAF, platelet-activating factor
- PEA, palmitoyl ethanolamide
- PMSF, phenylmethylsulfonyl fluoride
- Pre-analytics
- RT, room temperature
- SPE, solid-phase extraction
- WB, whole blood
Collapse
Affiliation(s)
- Daniel Kratz
- Institute of Clinical Pharmacology, pharmazentrum frankfurt/ZAFES, University Hospital of Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - Dominique Thomas
- Institute of Clinical Pharmacology, pharmazentrum frankfurt/ZAFES, University Hospital of Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), and Fraunhofer Cluster of Excellence for Immune Mediated Diseases (CIMD), Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany
| | - Robert Gurke
- Institute of Clinical Pharmacology, pharmazentrum frankfurt/ZAFES, University Hospital of Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), and Fraunhofer Cluster of Excellence for Immune Mediated Diseases (CIMD), Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany
| |
Collapse
|
4
|
Senta I, Rodríguez-Mozaz S, Corominas L, Petrovic M. Wastewater-based epidemiology to assess human exposure to personal care and household products - A review of biomarkers, analytical methods, and applications. Trends Environ Anal Chem 2020; 28:e00103. [PMID: 38620429 PMCID: PMC7470864 DOI: 10.1016/j.teac.2020.e00103] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Revised: 08/26/2020] [Accepted: 08/28/2020] [Indexed: 05/24/2023]
Abstract
Humans are nowadays exposed to numerous chemicals in our day-to-day life, including parabens, UV filters, phosphorous flame retardants/plasticizers, bisphenols, phthalates and alternative plasticizers, which can have different adverse effects to human health. Estimating human's exposure to these potentially harmful substances is, therefore, of paramount importance. Human biomonitoring (HBM) is the existing approach to assess exposure to environmental contaminants, which relies on the analysis of specific human biomarkers (parent compounds and/or their metabolic products) in biological matrices from individuals. The main drawback is its implementation, which involves complex cohort studies. A novel approach, wastewater-based epidemiology (WBE), involves estimating exposure from the analysis of biomarkers in sewage (a pooled urine and feces sample of an entire population). One of the key challenges of WBE is the selection of biomarkers which are specific to human metabolism, excreted in sufficient amounts, and stable in sewage. So far, literature data on potential biomarkers for estimating exposure to these chemicals are scattered over numerous pharmacokinetic and HBM studies. Hence, this review provides a list of potential biomarkers of exposure to more than 30 widely used chemicals and report on their urinary excretion rates. Furthermore, the potential and challenges of WBE in this particular field is discussed through the review of pioneer WBE studies, which for the first time explored applicability of this novel approach to assess human exposure to environmental contaminants. In the future, WBE could be potentially applied as an "early warning system", which could promptly identify communities with the highest exposure to environmental contaminants.
Collapse
Key Words
- 3−OH-EtP, ethyl protocatechuate
- 3−OH-MeP, methyl protocatechuate
- 5−OH−OC, 2-ethyl-5-hydroxyhexyl 2-cyano-3,3-diphenyl acrylate
- ASE, accelerated solvent extraction
- BBOEHEP, bis(2-butoxyethyl) 2-hydroxyethyl phosphate
- BBOEP, bis(2-butoxyethyl) phosphate
- BP-3, 2,4-dihydroxybenzophenone (Benzophenone-3, Oxybenzone)
- BPA, bisphenol A
- BPA-Glu, bisphenol A glucuronide
- BPA-SO4, bisphenol A sulfate
- Biomarkers
- Bisphenols
- CPAA, 2-cyano-3,3-diphenylacrylic acid
- DEHA, di-2-ethylhexyl adipate
- DEHP, di(2-ethylhexyl) phthalate
- DEHTP, di(2-ethylhexyl) terephthalate
- DHB, 2,4-dihydroxybenzophenone (Benzophenone-1, BP-1)
- DHMB, 2,2′-dihydroxy-4-methoxybenzophenone (Benzophenone-8, BP-8)
- DINCH, di(isononyl)cyclohexane-1,2-dicarboxylate
- DNBP, di-n-butyl phosphate
- DPHP, di-(2-propylheptyl) phthalate
- DPhP, diphenyl phosphate
- EHDPhP, 2-ethylhexyldiphenyl phosphate
- EHS, 2-ethylhexyl salicylate (Octisalate)
- EI, electron ionization
- ESI, electrospray ionization
- EtP, ethylparaben
- Excretion rate
- Flame retardants
- GC–MS, gas chromatography‒mass spectrometry
- HBM, human biomonitoring
- HPLC-MS/MS, high performance liquid chromatography–tandem mass spectrometry
- LC–MS/MS, liquid chromatography‒tandem mass spectrometry
- MAE, microwave-assisted extraction
- MEHA, mono-2-ethylhexyl adipate
- MINCH, Monoisononyl-cyclohexane-1,2-dicarboxylate
- MQL, method quantification limit
- MRM, multiple reaction monitoring (MRM)
- MTBSTFA, N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide
- MeP, methylparaben
- OC, Octocrylene
- OH-MINCH, Cyclohexane-1,2-dicarboxylate-mono-(7-hydroxy-4-methyl) octyl ester
- PE, primary effluent
- PFRs, phosphorous flame retardants/plasticizers
- PHBA, p-hydroxybenzoic acid
- PHHA, p-hydroxyhippuric acid
- Parabens
- Phthalates
- Plasticizers
- PrP, propylparaben
- Q-ToF, quadrupole-time-of-flight
- QTRAP, quadrupole-ion trap
- QqQ, triple quadrupole
- RW, raw wastewater
- SE, secondary (final) effluent
- SIM, selected ion monitoring
- SPE, solid-phase extraction
- SPM, suspended particulate matter
- Sewage chemical information mining
- Sewage epidemiology
- TBOEP, tris(2-butoxyethyl) phosphate
- TPhP, triphenyl phosphate
- UAE, ultrasonic-assisted extraction
- UHPLC-MS/MS, ultrahigh performance liquid chromatography–tandem mass spectrometry
- UV filters
- WBE, wastewater-based epidemiology
- WWTPs, wastewater treatment plants
- bbCID, broadband collision-induced dissociation
Collapse
Affiliation(s)
- Ivan Senta
- Catalan Institute for Water Research (ICRA), Emili Grahit 101, 17003 Girona, Spain
- Division for Marine and Environmental Research, Rudjer Boskovic Institute, Bijenicka 54, 10000 Zagreb, Croatia
| | - Sara Rodríguez-Mozaz
- Catalan Institute for Water Research (ICRA), Emili Grahit 101, 17003 Girona, Spain
- University of Girona, Girona, Spain
| | - Lluís Corominas
- Catalan Institute for Water Research (ICRA), Emili Grahit 101, 17003 Girona, Spain
- University of Girona, Girona, Spain
| | - Mira Petrovic
- Catalan Institute for Water Research (ICRA), Emili Grahit 101, 17003 Girona, Spain
- Catalan Institution for Research and Advanced Studies (ICREA), Passeig Lluís Companys 23, 08010, Barcelona, Spain
| |
Collapse
|
5
|
Wang G, Zhao D, Chen H, Ding D, Kou L, Sun L, Hao C, Li X, Jia K, Kan Q, Liu X, He Z, Sun J. Development and validation of a UPLC-MS/MS assay for the determination of gemcitabine and its L-carnitine ester derivative in rat plasma and its application in oral pharmacokinetics. Asian J Pharm Sci 2017; 12:478-485. [PMID: 32104361 PMCID: PMC7032160 DOI: 10.1016/j.ajps.2017.01.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2016] [Accepted: 01/05/2017] [Indexed: 01/20/2023] Open
Abstract
A simple and rapid UPLC–MS/MS method to simultaneously determine gemcitabine and its L-carnitine ester derivative (2'-deoxy-2', 2'-difluoro-N-((4-amino-4-oxobutanoyl) oxy)-4-(trimethyl amm-onio) butanoate-cytidine, JDR) in rat plasma was developed and validated. The conventional plasma sample preparation method of nucleoside analogues is solid-phase extraction (SPE) which is time-consuming and cost-expensive. In this study, gradient elution with small particles size solid phase was applied to effectively separate gemcitabine and JDR, and protein precipitation pretreatment was adopted to remove plasma protein and extract the analytes with high recovery(>81%). Method validation was performed as per the FDA guidelines, and the standard curves were found to be linear in the range of 5–4000 ng/ml for JDR and 4–4000 ng/ml for gemcitabine, respectively. The lower limit of quantitation (LLOQ) of gemcitabine and JDR was 4 and 5 ng/ml, respectively. The intra-day and inter-day precision and accuracy results were within the acceptable limits. Finally, the developed method was successfully applied to investigate the pharmacokinetic studies of JDR and gemcitabine after oral administration to rats.
Collapse
Key Words
- ESI, electrospray ionization
- Gemcitabine
- IS, internal standard
- JDR, 2'-deoxy-2', 2'-difluoro-N-((4-amino-4-oxobutanoyl)oxy)-4-(trimethyl amm-onio) butanoate-cytidine
- L-carnitine
- LLOQ, lower limit of quantification
- OCTN2, organic cation/carnitine transporters 2
- PK, pharmacokinetic
- Pharmacokinetics
- Prodrug
- QC, quality control
- SPE, solid-phase extraction
- THU, Tetrahydrouridine
- UPLC/MS/MS
Collapse
Affiliation(s)
- Gang Wang
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China
| | - Dongyang Zhao
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China
| | - Hongxiang Chen
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China
| | - Dawei Ding
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China
| | - Longfa Kou
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China
| | - Lifang Sun
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China
| | - Chenxia Hao
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China
| | - Xincong Li
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China
| | - Kai Jia
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China
| | - Qiming Kan
- Department of Pharmacology, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China
| | - Xiaohong Liu
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China
| | - Zhonggui He
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China
| | - Jin Sun
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No.103, Shenyang 110016, China.,Municipal Key Laboratory of Biopharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, China
| |
Collapse
|